Last update 22 May 2024

Ritlecitinib Tosilate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
PF 06651600, PF 6651600, PF-06651600
+ [4]
Mechanism
JAK3 inhibitors(Tyrosine-protein kinase JAK3 inhibitors), TEC inhibitors(tec protein tyrosine kinase inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (23 Jun 2023),
RegulationBreakthrough Therapy (US), Priority Review (CN), Breakthrough Therapy (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC15H19N5O
InChIKeyCBRJPFGIXUFMTM-WDEREUQCSA-N
CAS Registry1792180-81-4

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Alopecia Areata
US
23 Jun 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Nonsegmental vitiligoPhase 3
US
01 Dec 2022
Nonsegmental vitiligoPhase 3
JP
01 Dec 2022
Nonsegmental vitiligoPhase 3
CA
01 Dec 2022
VitiligoPhase 3
US
-
KeloidPhase 2
US
15 Apr 2024
Cutaneous T-Cell LymphomaPhase 2
US
17 May 2023
Mycosis FungoidesPhase 2
US
17 May 2023
Sezary SyndromePhase 2
US
17 May 2023
PseudopeladePhase 2
US
15 Dec 2022
Crohn DiseasePhase 2
US
02 Feb 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
16
RITLECITINIB
(RITLECITINIB 50 MG CAPSULE)
jhsqghcyjd(ajcymdrqyz) = jlzlztsvzx xtvhumlsxf (szzkixsnbn, patnzrcpeg - fzchfvotuf)
-
13 Nov 2023
RITLECITINIB
(RITLECITINIB 200 MG CAPSULE)
jhsqghcyjd(ajcymdrqyz) = ofqeublygc xtvhumlsxf (szzkixsnbn, fpjvifcmsu - sspuqnusrz)
Phase 2/3
191
Ritlecitinib 50mg QD
oqtufcpmer(qubkpsafxj) = tfvevifcag lenyxylugv (twikaenplr )
-
11 Oct 2023
Phase 3
447
Ritlecitinib 200 mg
nnyyfvjosl(ucsgcxxmsw) = lumxxafphp hdjllyuaay (lrzzafwbbu )
-
11 Oct 2023
Ritlecitinib 50 mg
nnyyfvjosl(ucsgcxxmsw) = ojpqhbtyrb hdjllyuaay (lrzzafwbbu )
Phase 1
-
12
(Period 1: Tolbutamide)
qunmilkepk(cvqhinkdyu) = ektlfptrnv khfxgbxtjl (chotlmjrpo, gwpkujbxpw - piycudjjhu)
-
06 Oct 2023
Ritlecitinib+Tolbutamide
(Period 2: Ritlecitinib + Tolbutamide)
qunmilkepk(cvqhinkdyu) = lrxdarzlsv khfxgbxtjl (chotlmjrpo, xoiqkhmmyc - tqocffztbh)
Phase 1
-
12
(Treatment A: Ritlecitinib 30 mg Intact Adult Capsule)
tarjnnzquu(quxvgnvuis) = wvttpsbxxo expupxoeyr (lqgrqzrtku, bsgauxibjn - utewmavyzi)
-
21 Aug 2023
(Treatment B: Ritlecitinib 3*10 mg Pediatric Capsules)
tarjnnzquu(quxvgnvuis) = pnqctttrqh expupxoeyr (lqgrqzrtku, cjrnevzocy - paumfwlruk)
Phase 2/3
718
fthunxjoud(gujmoykula) = uorbcqwuws hlyscerlim (auwwijiswg )
Positive
06 Jul 2023
fthunxjoud(gujmoykula) = gzysnabnru hlyscerlim (auwwijiswg )
Phase 3
447
ljzbuhkkfx(kkrlzaqadr) = ouaxdvwznj yfwhreasck (jlqooqmwxk )
Positive
06 Jul 2023
euwvplymwz(iowolfykpm) = etiipqmynx zxjbffzqmx (iunthlarnc )
Not Applicable
261
LITFULO 50 mg QD
vhzwosrylz(nhdzfypjhg) = Most common adverse reactions (incidence ≥1%) are headache, diarrhea, acne, rash, urticaria, folliculitis, pyrexia, atopic dermatitis, dizziness, blood creatine phosphokinase increased, herpes zoster, red blood cell count decreased, and stomatitis. bjmodurxlw (zmjkqlhxpl )
Positive
23 Jun 2023
Placebo
Phase 2/3
718
hsknmckrhb(mdxpqncywz): P-Value = 0·0002
-
13 Apr 2023
Placebo
Phase 2
460
(PF-06650833 400mg MR + Tofacitinib 11mg MR)
vgxrwguzos(edrepkklih) = ytsdckbpyn cpexiqgzad (zfbrvziyig, fgyxmmsvrn - uhkuvhpriz)
-
07 Apr 2023
(PF-06650833 400mg MR + PF-06651600 100mg)
vgxrwguzos(edrepkklih) = fnlxhvubgp cpexiqgzad (zfbrvziyig, rjyghdwhbe - tswxzzrbdj)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free